doing business with OMRIX

Through partnerships, OMRIX seeks to further develop, manufacture, and commercialize its products. We are currently collaborating with several companies whose own expertise complements our strengths in the areas of development and manufacturing. Through partnerships, we intend to focus on additional indications for existing products and product extensions, develop and launch products that integrate biological components and medical devices for the biosurgical market, and expand our core technology.

Our objective when collaborating with other companies is to diversify our development risk, develop multiple products with limited financial risk, efficiently market our products, and quickly establish significant market share in new territories.

Our partnering strategy is primarily focused on two areas:

Biosurgical Products

OMRIX is currently partnered with Ethicon Inc., a Johnson and Johnson company, in the development of four new biosurgical products: Evicel™, thrombin, flowable thrombin, and the Fibrin Patch.

We have also entered into a collaboration agreement with Aeris Therapeutics, Inc. in the development of product candidates for site-specific treatment of tissue and tissue regeneration.

Passive Immunotherapy Products

With our passive immunotherapy product pipeline, we intend to further refine our hyperimmune capabilities and exploit our manufacturing know-how to rapidly commercialize products that address existing and emerging infectious disease and potential bioterrorism threats.

We have partnered with the NIH in the U.S. to conduct a clinical study with our WNV enriched globulin preparation (WNIG) and were granted several grants for the development of our H-T VIG and west nile hyperimmunes. We have also entered into a CRADA agreement with the NIH for the development of an avian flu immunoglobulin.